Lyophilized Lentiviral Vector Particles Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for lyophilizing lentiviral vector particles are unsuitable for pharmaceutical applications due to contamination issues and instability, as they incorporate incompatible components like serum albumin and polyethylene glycol, which compromise the purity and stability of the viral vectors.
Innovation Solution
A method involving purification, concentration, freezing, and lyophilization of lentiviral vector particles in the absence of serum albumin and polyethylene glycol, using lyoprotectants like sucrose and trehalose to maintain stability and purity, and storing them for extended periods without significant loss of infectious titer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional lyophilization methods are used to stabilize lentiviral vector particles, then stability during storage is improved, but purity and compatibility for pharmaceutical applications deteriorate due to contamination with serum albumin and polyethylene glycol
Solution Approach 1:
The patent applies extraction by removing contaminating substances (serum albumin and polyethylene glycol) from the lentiviral vector formulation before lyophilization. This is achieved through purification steps that eliminate these incompatible components while retaining the viral vectors, thereby achieving both stability and pharmaceutical-grade purity
Solution Approach 2:
The patent changes the formulation parameters by using alternative stabilizing agents that are pharmaceutically compatible. Instead of serum albumin and polyethylene glycol, the invention employs purified lentiviral vectors with controlled composition parameters, enabling lyophilization that maintains both stability and purity
2Stability of the object's composition
If serum albumin and polyethylene glycol are used as stabilizing agents during lyophilization, then vector stability is improved, but compatibility for therapeutic administration deteriorates
Solution Approach 1:
The patent converts the harmful effect of stabilizing agents into a benefit by eliminating the need for incompatible substances. Through careful formulation and purification, the invention achieves vector stability during lyophilization without requiring serum albumin or polyethylene glycol, thereby converting a potentially harmful formulation approach into a safe, pharmaceutical-grade product
3Stability of the object's composition
If contaminants are present in the lentiviral vector formulation, then stability during lyophilization is improved, but suitability for pharmaceutical applications deteriorates
Solution Approach 1:
The patent applies extraction by removing contaminants from the lentiviral vector formulation through purification steps. This eliminates substances that would compromise pharmaceutical suitability while maintaining the stability needed for successful lyophilization, achieving both goals simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces highly stable lyophilized lentiviral vector particles with retained infectious titer, suitable for pharmaceutical use, by minimizing contaminants and using stabilizing agents to maintain vector integrity during storage.
Implementation Method 1
Lyophilisation (or Freeze-Drying) is a formulation approach used in the pharmaceutical industry for the stabilisation of products
Implementation Method 2
During drying, removal of stabilizing hydration shells can also influence stability
Implementation Method 3
During drying, removal of stabilizing hydration shells can also influence stability
Data Source
AI summary
Methods of making lyophilized lentiviral vector particles are provided. Compositions comprising lyophilized lentiviral vector particles are also provided. Methods of administering a lentiviral vector particle to a subject and uses of lentiviral vector particle compositions are also provided.